Raleukin

Raleukin (AMG-719) is a recombinant, nonglycosylated human interleukin-1 receptor (IL-1R) antagonist. Raleukin significantly reduces neutrophil accumulation in blood vessels and brain infarct volume as well as improves motor coordination performance in ischemic stroke mice model. Anakinra can be used to study chronic inflammatory disorders like rheumatoid arthritis and cardiovascular recurrence post-myocardial infarction[1][2][3].

Product Specifications

CAS Number

[143090-92-0]

Product Name Alternative

Kineret; Anakinra

UNSPSC

12352203

Target

Interleukin Related

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/anakinra.html

Purity

99.40

Solubility

DMSO : < 1 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

[Raleukin]

Molecular Formula

C759H1186N208O232S10

Molecular Weight

(17.3 kDa)

References & Citations

[1]Cvetkovic RS, et al. Anakinra. BioDrugs. 2002;16 (4) :303-11; discussion 313-4.|[2]McCall M, et al. Anakinra potentiates the protective effects of etanercept in transplantation of marginal mass human islets in immunodeficient mice. Am J Transplant. 2012 Feb;12 (2) :322-9.|[3]Harnack U, et al. IL-1 receptor antagonist anakinra enhances tumour growth inhibition in mice receiving peptide vaccination and beta- (1-3), (1-6) -D-glucan. Anticancer Res. 2010 Oct;30 (10) :3959-65.|[4]Huang X, et al. Microglial IL-1RA ameliorates brain injury after ischemic stroke by inhibiting astrocytic CXCL1-mediated neutrophil recruitment and microvessel occlusion. Glia. 2023 Jul;71 (7) :1607-1625.